On September 22, 2026, biotechnology developer Halozyme Therapeutics, Inc. completed its private offering of $1,500.0 million aggregate principal amount of 1.50% convertible senior notes due 2033 under Rule 144A. The transaction closed following the full exercise of a $200.0 million overallotment option by the initial purchasers. By combining the low-coupon debt issuance with $187.5 million in derivative capped call contracts and $652.5 million in cash repurchases of near-term convertible notes due in 2027 and 2028, Halozyme restructured its liability structure, eliminated imminent debt maturities, and retained approximately $631.1 million in net cash proceeds for corporate expansion.
Capital Structure Transformation and Debt Refinancing
Convertible debt has emerged as a preferred funding mechanism for profitable biopharmaceutical companies navigating fluctuating interest rate environments, as seen in other recent corporate debt deals like CoreWeave’s convertible debt sale. Halozyme’s execution on September 22, 2026 represents a proactive liability management maneuver. Rather than waiting for its older convertible paper to mature over the next 24 months, the company used favorable secondary pricing to retire existing debt while locking in an annual cash coupon of just 1.50% through October 2033.
According to Halozyme’s Form 8-K filed with the SEC, the offering generated net proceeds of approximately $1,471.1 million after deducting $28.9 million in initial purchasers’ discounts, commissions, and estimated offering expenses. The proceeds were deployed across three targeted buckets: derivative dilution mitigation, existing bond repurchases, and balance sheet cash accumulation.
| Transaction Component | Face Amount | Cash Consideration | Stated Terms & Objectives |
|---|---|---|---|
| New 2033 Convertible Notes | $1,500.0M | $1,471.1M (net) | 1.50% coupon; matures Oct 1, 2033; $139.84 initial conversion price |
| Capped Call Transactions | N/A | $187.5M | Hedges economic dilution up to $208.39 cap price per share |
| 2027 Notes Repurchase | $151.7M | $217.0M | Extinguishes 0.25% notes due 2027; includes accrued interest |
| 2028 Notes Repurchase | $220.0M | $435.5M | Extinguishes 1.00% notes due 2028; includes accrued interest |
| Retained Net Proceeds | N/A | $631.1M | General corporate purposes, strategic M&A, and future note repurchases |
Conversion Mechanics and Capped Call Dilution Protection
The 2033 notes carry an initial conversion rate of 7.1509 shares of common stock per $1,000 principal amount, which translates to an initial conversion price of approximately $139.84 per share. Under the terms of the indenture dated September 22, 2026 with The Bank of New York Mellon Trust Company, N.A. as trustee, the notes pay interest semi-annually in arrears on April 1 and October 1 of each year, with the initial coupon payment scheduled for April 1, 2027.
To insulate existing equity holders from immediate share overhang, Halozyme directed approximately $187.5 million of the net proceeds into privately negotiated capped call transactions with financial counterparties. These derivative contracts establish an initial cap price of $208.39 per share. If the convertible notes are converted in the future, the capped call structure is designed to offset equity dilution up to that cap price, providing management with equity-like capital while protecting common shareholders against dilution across a wide trading range. For readers tracking capital structures, our markets learning hub explains how hybrid debt securities balance coupon savings against dilution risk.
Balance Sheet Impact and Liquidity Bridge
Prior to this transaction, Halozyme’s balance sheet showed substantial operational strength but an upcoming debt maturity cluster. In its Form 10-Q for the quarter ended June 30, 2026, Halozyme reported $163.1 million in cash and cash equivalents and $67.9 million in available-for-sale marketable securities, totaling $231.0 million in liquid reserves. The filing specifically noted that cash and cash equivalents consisted of money market funds, bank certificate of deposits and demand deposits at commercial banks.
On the liabilities side, Halozyme reported $209.0 million in current long-term debt and $1,937.7 million in net non-current long-term debt as of June 30, 2026. The retirement of $151.7 million in 2027 notes and $220.0 million in 2028 notes eliminates $371.7 million in face-value debt obligations over the next two years. Because the notes traded at premiums above par reflecting equity appreciation, the cash outlay of $652.5 million fully satisfies those liabilities while pushing the issuer’s primary refinancing obligation outward to October 2033.
After paying $187.5 million for the capped calls and $652.5 million for the debt repurchases, Halozyme retains approximately $631.1 million in unallocated net cash. Combined with its existing $231.0 million in cash and marketable securities as of June 30, 2026, the company’s total pro-forma liquidity expands to over $860 million. Management disclosed that these funds will support ongoing clinical pipeline investments, potential strategic acquisitions, and additional open-market or negotiated debt repurchases.
What Capital Markets Are Watching Next
With the 2033 notes successfully priced and closed, institutional investors will watch several key milestones over the coming quarters:
- Third-Quarter 2026 Accounting Treatment: How Halozyme accounts for the early extinguishment of the 2027 and 2028 notes, including non-operating gains or charges resulting from repurchasing bonds above carrying value.
- M&A and Corporate Development: Deployment of the $631.1 million in fresh liquidity toward commercial-stage biopharma drug delivery technologies.
- Secondary Market Trading: The yield and conversion premium behavior of the 1.50% 2033 notes in the secondary market relative to prevailing benchmark rates.
Disclosure: This article is for informational purposes only and is not investment advice.
Sources
- U.S. Securities and Exchange Commission: Halozyme Therapeutics, Inc. Form 8-K (Item 1.01 Entry into a Material Definitive Agreement, Item 2.03 Creation of a Direct Financial Obligation), filed September 22, 2026.
- U.S. Securities and Exchange Commission: Halozyme Therapeutics, Inc. Form 10-Q for the Quarterly Period Ended June 30, 2026.